The references for supplementary table 1
[1] Y.Y. Wang, Z.Y. Ye, Z.S. Zhao, L. Li, Y.X. Wang, H.Q. Tao, H.J. Wang, X.J. He,
Clinicopathologic significance of miR-10b expression in gastric carcinoma, Human
pathology, 44 (2013) 1278-1285.
[2] M. Wang, H. Gu, S. Wang, H. Qian, W. Zhu, L. Zhang, C. Zhao, Y. Tao, W. Xu,
Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer, Molecular
medicine reports, 5 (2012) 1514-1520.
[3] K. Motoyama, H. Inoue, K. Mimori, F. Tanaka, K. Kojima, H. Uetake, K.
Sugihara, M. Mori, Clinicopathological and prognostic significance of PDCD4 and
microRNA-21 in human gastric cancer, International journal of oncology, 36 (2010)
1089-1095.
[4] Y. Xu, J. Sun, J. Xu, Q. Li, Y. Guo, Q. Zhang, miR-21 Is a Promising Novel
Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer,
Gastroenterology research and practice, 2012 (2012) 640168.
[5] S.H. Chan, C.W. Wu, A.F. Li, C.W. Chi, W.C. Lin, miR-21 microRNA expression
in human gastric carcinomas and its clinical association, Anticancer research, 28
(2008) 907-911.
[6] S. Komatsu, D. Ichikawa, M. Tsujiura, H. Konishi, H. Takeshita, H. Nagata, T.
Kawaguchi, S. Hirajima, T. Arita, A. Shiozaki, T. Kubota, H. Fujiwara, K. Okamoto,
E. Otsuji, Prognostic impact of circulating miR-21 in the plasma of patients with
gastric carcinoma, Anticancer research, 33 (2013) 271-276.
[7] W. Wang, F. Li, Y. Zhang, Y. Tu, Q. Yang, X. Gao, Reduced expression of miR-22
in gastric cancer is related to clinicopathologic characteristics or patient prognosis,
Diagnostic pathology, 8 (2013) 102.
[8] Y. Duan, L. Hu, B. Liu, B. Yu, J. Li, M. Yan, Y. Yu, C. Li, L. Su, Z. Zhu, M. Xiang,
B. Liu, Q. Yang, Tumor suppressor miR-24 restrains gastric cancer progression by
downregulating RegIV, Molecular cancer, 13 (2014) 127.
[9] M. Deng, H.L. Tang, X.H. Lu, M.Y. Liu, X.M. Lu, Y.X. Gu, J.F. Liu, Z.M. He,
miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer,
PloS one, 8 (2013) e72662.
[10] Q. Yang, Z. Jie, S. Ye, Z. Li, Z. Han, J. Wu, C. Yang, Y. Jiang, Genetic variations
in miR-27a gene decrease mature miR-27a level and reduce gastric cancer
susceptibility, Oncogene, 33 (2014) 193-202.
[11] D. Liu, Q. Sun, S. Liang, L. Xu, X. Luo, X. Zhao, X. Wang, L. Yang,
MicroRNA-27a inhibitors alone or in combination with perifosine suppress the
growth of gastric cancer cells, Molecular medicine reports, 7 (2013) 642-648.
[12] L. Chen, M. Jiang, W. Yuan, H. Tang, Prognostic value of miR-93 overexpression
in resectable gastric adenocarcinomas, Acta gastro-enterologica Belgica, 75 (2012)
22-27.
[13] T. Inoue, H. Iinuma, E. Ogawa, T. Inaba, R. Fukushima, Clinicopathological and
prognostic significance of microRNA-107 and its relationship to DICER1 mRNA
expression in gastric cancer, Oncology reports, 27 (2012) 1759-1764.
[14] H. Li, S. Xie, M. Liu, Z. Chen, X. Liu, L. Wang, D. Li, Y. Zhou, The clinical
significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and
mir-335-5p in gastric cancer tumorigenesis, International journal of oncology, 45
(2014) 197-208.
[15] Y. Hashiguchi, N. Nishida, K. Mimori, T. Sudo, F. Tanaka, K. Shibata, H. Ishii, H.
Mochizuki, K. Hase, Y. Doki, M. Mori, Down-regulation of miR-125a-3p in human
gastric cancer and its clinicopathological significance, International journal of
oncology, 40 (2012) 1477-1482.
[16] N. Nishida, K. Mimori, M. Fabbri, T. Yokobori, T. Sudo, F. Tanaka, K. Shibata, H.
Ishii, Y. Doki, M. Mori, MicroRNA-125a-5p is an independent prognostic factor in
gastric cancer and inhibits the proliferation of human gastric cancer cells in
combination with trastuzumab, Clinical cancer research : an official journal of the
American Association for Cancer Research, 17 (2011) 2725-2733.
[17] R. Feng, X. Chen, Y. Yu, L. Su, B. Yu, J. Li, Q. Cai, M. Yan, B. Liu, Z. Zhu,
miR-126 functions as a tumour suppressor in human gastric cancer, Cancer letters,
298 (2010) 50-63.
[18] X. Liu, H. Yu, H. Cai, Y. Wang, The expression and clinical significance of
miR-132 in gastric cancer patients, Diagnostic pathology, 9 (2014) 57.
[19] Y. Naito, N. Sakamoto, N. Oue, M. Yashiro, K. Sentani, K. Yanagihara, K.
Hirakawa, W. Yasui, MicroRNA-143 regulates collagen type III expression in stromal
fibroblasts of scirrhous type gastric cancer, Cancer science, 105 (2014) 228-235.
[20] S. Akiyoshi, T. Fukagawa, H. Ueo, M. Ishibashi, Y. Takahashi, M. Fabbri, M.
Sasako, Y. Maehara, K. Mimori, M. Mori, Clinical significance of miR-144-ZFX axis
in disseminated tumour cells in bone marrow in gastric cancer cases, British journal of
cancer, 107 (2012) 1345-1353.
[21] R. Kogo, K. Mimori, F. Tanaka, S. Komune, M. Mori, Clinical significance of
miR-146a in gastric cancer cases, Clinical cancer research : an official journal of the
American Association for Cancer Research, 17 (2011) 4277-4284.
[22] G. Chen, Z.-L. Shen, L. Wang, C.-Y. Lv, X.-E. Huang, R.-P. Zhou,
Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer,
Asian Pacific Journal of Cancer Prevention, 14 (2013) 3871-3875.
[23] J.Y. Lim, S.O. Yoon, S.Y. Seol, S.W. Hong, J.W. Kim, S.H. Choi, J.S. Lee, J.Y.
Cho, Overexpression of miR-196b and HOXA10 characterize a poor-prognosis
gastric cancer subtype, World J Gastroenterol, 19 (2013) 7078-7088.
[24] Z. Wang, X. Ma, Q. Cai, X. Wang, B. Yu, B. liu, Z. Zhu, C. Li, MiR-199a-3p
promotes gastric cancer progression by targeting ZHX1. FEBS letters 588 (2014)
4504-4512.
[25] C. Li, J.F. Li, Q. Cai, Q.Q. Qiu, M. Yan, B.Y. Liu, Z.G. Zhu, miRNA-199a-3p in
plasma as a potential diagnostic biomarker for gastric cancer, Journals of surgical
oncology, 20 Suppl 3 (2013) S397-405.
[26] H. Tang, M. Deng, Y. Tang, X. Xie, J. Guo, Y. Kong, F. Ye, Q. Su, X. Xie,
miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell
progression, Clinical cancer research : an official journal of the American Association
for Cancer Research, 19 (2013) 5602-5612.
[27] J. Kurashige, H. Kamohara, M. Watanabe, Y. Hiyoshi, M. Iwatsuki, Y. Tanaka, K.
Kinoshita, S. Saito, Y. Baba, H. Baba, MicroRNA-200b regulates cell proliferation,
invasion, and migration by directly targeting ZEB2 in gastric carcinoma, Journals of
surgical oncology, 19 Suppl 3 (2012) S656-664.
[28]J. Kurashige, K. Mima, G. Sawada, Y. Takahashi, H. Eguchi, K. Sugimachi, M.
Mori, K. Yanagihara, M. Yashiro, K. Hirakawa, H. Baba, K. Mimori, Epigenetic
modulation and repression of miR-200b by cancer-associated fibroblasts contribute to
cancer invasion and peritoneal dissemination in gastric cancer. Carcinogenesis 36
(2015) 133-141.
[29] M. Valladares-Ayerbes, M. Reboredo, V. Medina-Villaamil, P. Iglesias-Diaz, M.J.
Lorenzo-Patino, M. Haz, I. Santamarina, M. Blanco, J. Fernandez-Tajes, M. Quindos,
A. Carral, A. Figueroa, L.M. Anton-Aparicio, L. Calvo, Circulating miR-200c as a
diagnostic and prognostic biomarker for gastric cancer, Journal of translational
medicine, 10 (2012) 186.
[30] Q. Yang, C. Zhang, B. Huang, H. Li, R. Zhang, Y. Huang, J. Wang,
Downregulation of microRNA-206 is a potent prognostic marker for patients with
gastric cancer, European journal of gastroenterology & hepatology, 25 (2013)
953-957.
[31] M. Wang, C. Zhao, H. Shi, B. Zhang, L. Zhang, X. Zhang, S. Wang, X. Wu, T.
Yang, F. Huang, J. Cai, Q. Zhu, W. Zhu, H. Qian, W. Xu, Deregulated microRNAs in
gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a
mechanism for gastric cancer, British journal of cancer, 110 (2014) 1199-1210.
[32] Y. Deng, Z. Huang, Y. Xu, J. Jin, W. Zhuo, C. Zhang, X. Zhang, M. Shen, X. Yan,
L. Wang, X. Wang, Y. Kang, J. Si, T. Zhou, MiR-215 modulates gastric cancer cell
proliferation by targeting RB1, Cancer letters, 342 (2014) 27-35.
[33] X.D. Xu, X.J. He, H.Q. Tao, W. Zhang, Y.Y. Wang, Z.Y. Ye, Z.S. Zhao, Abnormal
expression of miR-301a in gastric cancer associated with progression and poor
prognosis, Journal of surgical oncology, 108 (2013) 197-202.
[34] M. Wang, C. Li, B. Yu, L. Su, J. Li, J. Ju, Y. Yu, Q. Gu, Z. Zhu, B. Liu,
Overexpressed miR-301a promotes cell proliferation and invasion by targeting
RUNX3 in gastric cancer, Journal of gastroenterology, 48 (2013) 1023-1033.
[35] P. Li, X. Chen, L. Su, C. Li, Q. Zhi, B. Yu, H. Sheng, J. Wang, R. Feng, Q. Cai, J.
Li, Y. Yu, M. Yan, B. Liu, Z. Zhu, Epigenetic silencing of miR-338-3p contributes to
tumorigenicity in gastric cancer by targeting SSX2IP, PloS one, 8 (2013) e66782.
[36] S.L. Guo, H. Ye, Y. Teng, Y.L. Wang, G. Yang, X.B. Li, C. Zhang, X. Yang, Z.Z.
Yang, X. Yang, Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric
tumorigenesis induced by PTEN deficiency, Nature communications, 4 (2013) 2544.
[37] C. Li, H. Nie, M. Wang, L. Su, J. Li, B. Yu, M. Wei, J. Ju, Y. Yu, M. Yan, Q. Gu,
Z. Zhu, B. Liu, MicroRNA-409-3p regulates cell proliferation and apoptosis by
targeting PHF10 in gastric cancer, Cancer letters, 320 (2012) 189-197.
[38] W. Li, X. Jin, X. Deng, G. Zhang, B. Zhang, L. Ma, The putative tumor
suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by
repressing eIF4E, Biochemical and biophysical research communications, 449 (2014)
235-240.
[39] M. Wang, C. Li, H. Nie, X. Lv, Y. Qu, B. Yu, L. Su, J. Li, X. Chen, J. Ju, Y. Yu,
M. Yan, Q. Gu, Z. Zhu, B. Liu, Down-regulated miR-625 suppresses invasion and
metastasis of gastric cancer by targeting ILK, FEBS letters, 586 (2012) 2382-2388.
[40] D. Chu, Z. Zhao, Y. Li, J. Li, J. Zheng, W. Wang, Q. Zhao, G. Ji, Increased
microRNA-630 expression in gastric cancer is associated with poor overall survival,
PloS one, 9 (2014) e90526.
[41] B. Jiang, Z. Li, W. Zhang, H. Wang, X. Zhi, J. Feng, Z. Chen, Y. Zhu, L. Yang, H.
Xu, Z. Xu, miR-874 Inhibits cell proliferation, migration and invasion through
targeting aquaporin-3 in gastric cancer, Journal of gastroenterology, 49 (2014)
1011-1025.
[42] L. Jia, J. Wu, L. Zhang, J. Chen, D. Zhong, S. Xu, C. Xie, J. Cai, Restoration of
miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer,
PloS one, 8 (2013) e58637.
[43] E.B. Zhang, L. Han, D.D. Yin, R. Kong, W. De, J. Chen, c-Myc-induced, long,
noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with
gastric cancer, Medical oncology, 31 (2014) 914.
[44] T. Arita, D. Ichikawa, H. Konishi, S. Komatsu, A. Shiozaki, K. Shoda, T.
Kawaguchi, S. Hirajima, H. Nagata, T. Kubota, H. Fujiwara, K. Okamoto, E. Otsuji,
Circulating long non-coding RNAs in plasma of patients with gastric cancer,
Anticancer research, 33 (2013) 3185-3193.
[45] M. Sun, F.Y. Jin, R. Xia, R. Kong, J.H. Li, T.P. Xu, Y.W. Liu, E.B. Zhang, X.H.
Liu, W. De, Decreased expression of long noncoding RNA GAS5 indicates a poor
prognosis and promotes cell proliferation in gastric cancer, BMC cancer, 14 (2014)
319.
[46] M. Sun, R. Xia, F. Jin, T. Xu, Z. Liu, W. De, X. Liu, Downregulated long
noncoding RNA MEG3 is associated with poor prognosis and promotes cell
proliferation in gastric cancer, Tumour biology : the journal of the International
Society for Oncodevelopmental Biology and Medicine, 35 (2014) 1065-1073.
[47] F. Yang, X. Xue, L. Zheng, J. Bi, Y. Zhou, K. Zhi, Y. Gu, G. Fang, Long
non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing
c-Myc mRNA stability, The FEBS journal, 281 (2014) 802-813.
[48] E.B. Zhang, R. Kong, D.D. Yin, L.H. You, M. Sun, L. Han, T.P. Xu, R. Xia, J.S.
Yang, W. De, J. Chen, Long noncoding RNA ANRIL indicates a poor prognosis of
gastric cancer and promotes tumor growth by epigenetically silencing of
miR-99a/miR-449a, Oncotarget, 5 (2014) 2276-2292.
[49] Z.Y. Xu, Q.M. Yu, Y.A. Du, L.T. Yang, R.Z. Dong, L. Huang, P.F. Yu, X.D.
Cheng, Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion
and reverses epithelial-mesenchymal transition in gastric cancer, International journal
of biological sciences, 9 (2013) 587-597.
[50]Y. Okugawa, Y. Toiyama, K. Hur, S. Toden, S. Saigusa, K. Tanaka, Y. Inoue, Y.
Mohri, M. Kusunoki, C.R. Boland, A. Goel, Metastasis-associated long non-coding
RNA drives gastric cancer development and promotes peritoneal metastasis.
Carcinogenesis 35 (2014) 2731-2739.
[51]B. Zhou, X.Y. Jing, J.Q. Wu, H.F. Xi, G.J. Lu, Down-regulation of long
non-coding RNA LET is associated with poor prognosis in gastric cancer.
International journal of clinical and experimental pathology 7 (2014) 8893-8898.
[52]J. Ding, D. Li, M. Gong, J. Wang, X. Huang, T. Wu, C. Wang, Expression and
clinical significance of the long non-coding RNA PVT1 in human gastric cancer.
OncoTargets and therapy 7 (2014) 1625-1630.
[53]T.P. Xu, M.D. Huang, R. Xia, X.X. Liu, M. Sun, L. Yin, W.M. Chen, L. Han, E.B.
Zhang, R. Kong, W. De, Y.Q. Shu, Decreased expression of the long non-coding RNA
FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates
gastric cancer cell metastasis by affecting fibronectin1 expression. Journal of
hematology & oncology 7 (2014) 63.
[54]C.Y. Wang, L. Hua, K.H. Yao, J.T. Chen, J.J. Zhang, J.H. Hu, Long non-coding
RNA CCAT2 is up-regulated in gastric cancer and associated with poor prognosis.
International journal of clinical and experimental pathology 8 (2015) 779-785.